title: Influence of the dopamine D2 receptor (DRD2) exon 8 genotype on efficacy of tiapride and clinical outcome of alcohol withdrawal.
abstract: We tested the hypothesis that allelic variants of the human dopamine D2 receptor E8 genotype are associated with (i) dopamine D2 antagonist tiapride dose in treatment of alcohol withdrawal (n = 50) and (ii) with anxiety and depression in patients during alcoholism detoxification therapy (admission n = 87; discharge n = 50). DRD2 E8 A/A genotype was associated with increased dose of tiapride during a 9-day detoxification therapy and with increased anxiety and depression scores on admission and 2 weeks later. The findings suggest a pharmacogenetic influence of DRD2 E8 genotype on tiapride efficacy in alcohol withdrawal. In an earlier report, DRD2 E8 A/A genotype was associated with reduced responsiveness to the dopamine D2 agonist apomorphine; however, it is not clear whether both findings share the same biological basis. Earlier findings concerning association of DRD2 E8 A/A with increased anxiety and depression are replicated for the first time.
authors.affiliation: Department of Psychiatry and Psychotherapy, University of Greifswald, Stralsund, Germany. lucht@mail.uni-greifswald.de
authors.forename: M J
authors.initials: MJ
authors.lastname: Lucht
authors.forename: K U
authors.initials: KU
authors.lastname: Kuehn
authors.forename: W
authors.initials: W
authors.lastname: Schroeder
authors.forename: J
authors.initials: J
authors.lastname: Armbruster
authors.forename: G
authors.initials: G
authors.lastname: Abraham
authors.forename: A
authors.initials: A
authors.lastname: Schattenberg
authors.forename: M
authors.initials: M
authors.lastname: Gaensicke
authors.forename: S
authors.initials: S
authors.lastname: Barnow
authors.forename: H
authors.initials: H
authors.lastname: Tretzel
authors.forename: F H
authors.initials: FH
authors.lastname: Herrmann
authors.forename: H J
authors.initials: HJ
authors.lastname: Freyberger
mesh_terms: D000328:Adult; D018492:Dopamine Antagonists / Q000627:therapeutic use; D000431:Ethanol / Q000009:adverse effects*; D005091:Exons / Q000235:genetics*; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D017354:Point Mutation / Q000235:genetics; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000235:genetics* / Q000523:psychology; D013976:Tiapamil Hydrochloride / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018492:Dopamine Antagonists; D017448:Receptors, Dopamine D2; D000431:Ethanol; D013976:Tiapamil Hydrochloride